An interventional study of Autologous Tooth Graft in Periodontal Defects After Third Molar Extraction and Periodontal Disease, sponsored by Universidad Complutense de Madrid. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Universidad Complutense de Madrid · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Periodontal Diseases with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Periodontal Diseases · Spain.
Among the 26 studies in Periodontal Diseases with a site in Spain, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, and was the 26th registered.
867 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.
Browse Periodontal Diseases studies →10 of the 26 studies in Periodontal Diseases with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Murcia · Sites in Spain
Ages 18–40
Universidad Complutense de Madrid · Sites in Spain
Ages 18+ · Healthy volunteers
Aesculap AG · Sites in Spain
Ages 18+
Universidad de Murcia · Sites in Spain
Ages 18–80
University of Barcelona · Sites in Spain
Ages 18+ · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 101 Periodontal Diseases studies recruiting now, 47 (47%) set no upper age limit and 42 (42%) stop at 75 or younger; 5 take children under 18; 58 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 30 is below the median of 45 across 557 interventional studies indexed under Periodontal Diseases.
Median enrollment 29 across the 18 interventional studies, 97 across the 8 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
Universidad Complutense de Madrid is the lead sponsor of 206 studies on the registry; 64 are open to participants now.
Universidad Complutense de Madrid has 5 studies filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Periodontal Diseases with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05813236Aesculap AGNOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery | 2026-11 |
| NCT03997552Universidad de MurciaNIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration | 2026-12-01 |
| NCT05533528Universidad de MurciaPeriodontal Granulation Tissue Preservation in Surgical Periodontitis Treatment | 2026-12-22 |
| NCT07718061Universidad de MurciaBacterial Diversity Study Using 16S rRNA Sequencing of Periodontal Samples From Patients With Orthodontic Retainers | 2027-07 |
| NCT07167771Universidad Complutense de MadridLONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in Periodontal Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the healing of periodontal defects on the distal surface of the second lower molars after the surgical extraction of impacted third molars. Specifically, it compares the effectiveness of autologous tooth graft particles (derived from the extracted third molar) with bovine xenograft particles, using blood clot healing as a control.
This study investigates the healing of periodontal defects on the distal surface of the second lower molars after the surgical extraction of impacted third molars. Specifically, it compares the effectiveness of autologous tooth graft particles (derived from the extracted third molar) with bovine xenograft particles, using blood clot healing as a control.
Lower third molars are the most frequently impacted teeth, and their extraction can sometimes lead to or worsen periodontal defects on the adjacent second molar. Previous studies have shown positive outcomes using various bone regeneration materials; however, autologous tooth grafts have recently emerged as a biocompatible, osteoconductive, and osteoinductive alternative with promising results. Despite this, there are no clinical studies directly comparing autologous tooth grafts and bovine xenografts in this context-justifying the present research.
A prospective, randomized split-mouth clinical trial with three arms will be conducted at the Complutense University of Madrid. Each patient will undergo bilateral lower third molar extractions under three conditions:
Group A (Test 1): socket filled with autologous tooth graft,
Group B (Test 2): socket filled with bovine xenograft,
Group C (Control): socket left to heal naturally with a blood clot.
The main objective is to evaluate the reduction in probing depth on the distal surface of the second molar six months post-extraction.
Secondary outcomes include postoperative pain, inflammation, trismus, complications, wound healing, and patient-reported outcomes (PoSSe questionnaire).
Approximately 30 patients will be included, with triple randomization (side of first extraction, use of graft, and graft type). Clinical and radiographic evaluations will be performed preoperatively, and follow-ups will occur at 48 hours, one week, three months, and six months.
The null hypothesis (H₀) states that there will be no periodontal differences between the two graft materials, while the alternative hypothesis (H₁) proposes superior periodontal outcomes with the autologous tooth graft compared to the bovine xenograft.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After surgical extraction of the impacted lower third molar, the socket will be filled with autologous tooth graft particles obtained from the extracted tooth using the Smart Dentin Grinder®. The graft particles (300-1200 µm) will be decontaminated, rinsed, and placed on the distal surface of the second molar. The graft will be covered with a resorbable hemostatic sponge (Roeko Gelatamp®) before suturing.
Biological: Autologous Tooth Graft
After extraction of the impacted lower third molar, the socket will be filled with particulate bovine xenograft (InterOss®) hydrated in sterile saline. The material will be placed on the distal surface of the second molar and covered with a resorbable hemostatic sponge before suturing.
Biological: Autologous Tooth Graft
Following extraction of the impacted lower third molar, the socket will be left to heal naturally through blood clot formation, without placement of any graft material or hemostatic sponge. Standard wound closure and postoperative care will be provided.
Autologous tooth graft particles are prepared from the extracted third molar using the Smart Dentin Grinder®. The tooth is cleaned, dried, and ground to particles of 300-1200 µm, decontaminated with 0.5 M sodium hydroxide and 20% ethanol, rinsed with sterile saline, and placed on the distal surface of the second molar. The graft is covered with a resorbable hemostatic sponge (Roeko Gelatamp®) prior to wound closure.
Also known as: Smart Dentin Grinder®
Reduction in probing depth on the distal surface of the mandibular second molar
Periodontal probing depth (in millimeters) measured on the distal surface of the lower second molar using a calibrated periodontal probe (CP12). The reduction in probing depth will be compared among the three groups (autologous tooth graft, bovine xenograft, and blood clot control) to evaluate periodontal healing following extraction of the lower third molars.
Time frame: Baseline (preoperative), 3 months, and 6 months post-extraction
Postoperative swelling
Facial swelling measured as the linear distance between anatomical landmarks (tragus-commissure, tragus-gonion, and gonion-commissure) using a suture thread and caliper.
Time frame: Preoperative, 48 hours, and 7 days post-extraction
Postoperative trismus
Maximum interincisal mouth opening measured in millimeters using a caliper.
Time frame: Preoperative, 48 hours, and 7 days post-extraction
Wound healing quality
linical evaluation of the surgical site according to Blum's criteria (good, acceptable, poor), based on mucosal color, bleeding, wound margins, and closure.
Time frame: 48 hours, and 7 days post-extraction
Patient-reported quality of life
Assessed using the Postoperative Symptom Severity (PoSSe) scale, covering pain, function, daily activities, and social interaction after surgery.
Time frame: 7 days post-extraction
Surgical time
Minutes and seconds recorded intraoperatively
Time frame: Intraoperatively
Surgical difficulty
Classified according to the modified Parant scale: Types I-IV
Time frame: Intraoperatively
Plan to share: Yes — Individual participant data (IPD) from this study will be shared with qualified researchers after the publication of primary results. Shared data will include anonymized measurements of periodontal probing depth, postoperative outcomes (pain, swelling, trismus), PoSSe questionnaire responses, and relevant demographic and clinical variables. Data will be de-identified to protect participant confidentiality.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: IPD will be available beginning 6 months after publication of the primary study results and will remain accessible for 5 years.
Access criteria: Data will be available to researchers who submit a written request describing the purpose of the analysis and who agree to a data use agreement ensuring confidentiality and appropriate use. Requests will be reviewed by the Principal Investigator or designated study committee.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.
Of 312 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 12 months is close to that.
Counting every sponsor, half of 331 studies reached it within 13 months; a quarter within 8 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Complutense de Madrid →